HHS is taking new steps to speed the development and review of new cell and gene therapies in the U.S.
Three things to know:
1. The FDA published three draft guidances Sept. 24 detailing strategies for drugmakers to streamline the development and approval of drug candidates to treat rare diseases that affect a small population of patients.
2. The documents promote the use of innovative clinical trial designs, outline paths for accelerated approval of certain regenerative therapies and clarify requirements for post-approval safety and efficacy monitoring.
3. The Advanced Research Projects Agency for Health, or ARPA-H, also launched two programs aimed at increasing access to affordable genetic medicines. One program focuses on accelerating development of one-time precision treatments for genetic diseases, while the other supports new biomanufacturing technologies to make these therapies faster and cheaper to produce.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
